drugset / Trial / NCT01721954

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT01721954 ↗

Phase 3 Completed 209 enrolled Sirtex Medical
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus FOLFOX6m alone as first-line therapy in patients with non-resectable liver metastases from primary colorectal carcinoma. Treatment with the biologic agent bevacizumab, if part of the standard of care at participating institutions, is allowed within this study at the discretion of the Investigator.

Timeline

Start
2013-05-01
Primary completion
2016-12-23
Completion
2017-02-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Leucovorin Small molecule 200 mg —
Background Oxaliplatin Small molecule 85 mg/m2 —
Background fluorouracil Small molecule 400 mg/m2 —
Background fluorouracil Small molecule 2400 mg/m2 —

Indications